PubMed
Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane
Szeto HH. AAPS J. 2006
Compare
SS-31 vs Tirzepatide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
SS-31
59 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 2% · Unfavorable overall 96%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
188
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
183
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.025 to ≥ 5 mg (open-ended top bucket)
0.025–0.05 mg
10
0.2–0.4 mg
2
0.4–0.6 mg
1
0.6–1 mg
4
1–2 mg
18
2–3 mg
21
3–5 mg
6
5+ mg
125
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 73 days · Based on 37 repeat reporters
Tirzepatide
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
7
Sleep
1
Mood
1
Energy
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Injection site irritation
3
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
0.4–0.6 mg
1
5+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Sources (13)
Published sources linked on the SS-31 and Tirzepatide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Elamipretide in patients with heart failure with a reduced ejection fraction: EMBRACE-HF
Butler J, Khan MS, Anker SD, et al. Eur J Heart Fail. 2020
- Wiki study page →Source
ClinicalTrials.gov
Elamipretide (SS-31) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Tung C, Varzideh F, Farroni E, et al. International journal of molecular sciences. 2025
- Wiki study page →Source
PubMed
Serendipity and the discovery of novel compounds that restore mitochondrial plasticity
Szeto HH, Birk AV. Clinical pharmacology and therapeutics. 2014
- Wiki study page →Source
FDA Drug Label
MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli Lilly. FDA Drug Label. 2022
- Wiki study page →Source
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022
- Wiki study page →Source
ClinicalTrials.gov
Tirzepatide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021
- Wiki study page →Source
PubMed
Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024
- Wiki study page →Source
FDA Drug Label
ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli Lilly. FDA Drug Label. 2023
- Wiki study page →Source
PubMed
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023
- Wiki study page →Source
PubMed
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025